कृपया अन्य खोज का प्रयास करें
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
An van Es-Johansson | 61 | 2021 | Independent Director |
Thomas A. Raffin | 74 | 1999 | Lead Independent Director |
Lota S. Zoth | 61 | 2012 | Independent Director |
Chad Allen Johnson | 42 | 2018 | Independent Director |
Mark A. Bach | 64 | 2021 | Scientific Advisory Board Member |
Kevin M. Lalande | 49 | 2014 | Independent Director |
Reiko Horikawa | - | - | Member of Scientific Advisory Board |
Joseph S. McCracken | 68 | 2020 | Independent Director |
George Werther | - | - | Member of Scientific Advisory Board |
Peter Clayton | - | - | Member of Scientific Advisory Board |
Ron Rosenfeld | - | - | Member of Scientific Advisory Board |
Richard J. Hawkins | 74 | 2011 | Founder, CEO & Chairman |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है